Journal of Clinical Oncology, Vol 15, 701-711, Copyright © 1997 by American Society of Clinical Oncology
Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus
G Ganem, B Dubray, Y Raoul, P Colin, E Bardet, JY Douillard, MJ Goudier, C Hennequin, S Walter, P Michel-Langlet, P Martin, D Maron, F Morvan, P Andolenko and JM Extra
Centre Jean Bernard, Le Mans, France. bggrpoc@cybercable.tm.fr
PURPOSE: To conduct a multicenter phase II study of a concomitant
combination of chemotherapy and radiotherapy followed by surgery, where
feasible, in patients with nonmetastatic esophageal tumor, stratified on
operability at diagnosis. METHODS: Each cycle consisted of fluorouracil
(5FU) 800 mg/m2/d by continuous intravenous (IV) infusion on days 1 to 5,
cisplatin (CDDP) 50 mg/m2/d IV bolus on days 1 and 8, hydroxyurea (HU) 1.5
or 2 g/d orally on days 8 to 12 and concomitant radiotherapy 20 Gy in 10
fractions over 12 days. All patients were to receive two cycles on days 1
and 22. If feasible, surgery was performed 3 to 6 weeks after cycle two
completion. Otherwise, a third cycle was administered. RESULTS:
Eighty-eight patients were included between September 1990 and September
1993. Of the 47 operable patients, 41 (87%) underwent surgery and 38 (81%)
had a complete resection. No residual primary tumor was found in the
surgical specimen in 17 cases (36%), and only microscopic foci in 13 (28%).
Two-year overall and disease-free survival probabilities were 51% (95%
confidence interval [CI]; 37 to 65) and 43% (95% CI, 28 to 57),
respectively. Among the 41 inoperable patients, 12 (29%) became operable.
Seven (17%) had complete resection, two incomplete resection, and three
exploratory surgery. Two- year overall and disease-free survival
probabilities were 29% (95% CI, 15 to 43) and 27% (95% CI, 13 to 40),
respectively. Five deaths occurred during chemoradiotherapy, six
postoperatively and four in patients with evidence of cancer. Five late
complications (one myelopathy) were observed. CONCLUSION: Despite a high
histologic response rate in initially operable patients, overall survival
was similar to that observed in other preoperative chemoradiation series
because of substantial toxicity.